
|Videos|March 30, 2021
Examining TKI Combinations in Advanced RCC
A panel discusses the role of TKI combination therapies for patients with advanced renal cell carcinoma and how they have changed the treatment landscape.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Final Approval to Cabozantinib Capsule Formulation
2
Risk-Adapted Quadruplet Therapy Sustains 5-Year Survival Benefit in High-Risk Myeloma
3
FDA Delays Decision on Zanzalintinib Combo for mCRC
4
Four Approvals Reflect Growth in Hormone-Sensitive Prostate Cancer Treatment
5







































